<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082962</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000127</org_study_id>
    <nct_id>NCT04082962</nct_id>
  </id_info>
  <brief_title>Dexamethasone Implant for Retinal Detachment in Uveal Melanoma</brief_title>
  <official_title>Dexamethasone Intravitreal Implant for the Management of Exudative Retinal Detachment in Patients With Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivana K. Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated Phase I study of a single dose of an
      intravitreally-administered dexamethasone implant (Ozurdex™) in subjects with uveal melanomas
      (UM) and exudative retinal detachments (ERD: build-up of fluid under the retina that causes
      it to detach) being treated with proton beam radiation (PBI). Although PBI is an effective
      treatment for UM, ERDs may persist after radiation, leading to vision loss. Effective
      treatments for ERD are currently lacking. We are conducting this study to evaluate whether
      Ozurdex™ can help resolve ERDs that occur in patients with UM. Ozurdex™ has been approved by
      the Food and Drug Administration (FDA) to treat certain ocular conditions such as macular
      edema, non-infectious uveitis, and diabetic macular edema but it is not approved for use in
      patients with UM and ERD. This study will determine the safety of the dexamethasone implant
      and provide preliminary evidence of efficacy in this population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Twenty patients will be enrolled in this randomized pilot study. Patients will be randomized (1:1) to receive the dexamethasone implant or no treatment. A stratified randomization scheme will be performed, with strata defined by tumor height (&lt; 5mm and 5mm - &lt; 9 mm). Patients with newly diagnosed choroidal melanoma meeting specified eligibility criteria will be randomly assigned to receive Ozurdex™ (0.7 mg dexamethasone) or no treatment at the time of their tumor localization (tantalum ring placement) surgery.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events Related to the Implant</measure>
    <time_frame>Throughout 12 month study period</time_frame>
    <description>The primary outcome of the study will be to evaluate the safety of the implant. All adverse effects not related to the melanoma or radiation treatment identified by ocular examination, diagnostic tests, and subject reporting will be tabulated. This includes significant vision loss, other sight-threatening events, and unforeseen systemic events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exudative retinal detachment resolution</measure>
    <time_frame>6 and 12 months after implant insertion</time_frame>
    <description>Will be assessed using spectral domain optical coherence tomography, B-scan ultrasonography, and optos wide-angle color photography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 and 12 months after implant insertion</time_frame>
    <description>Measured with ETDRS chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Throughout 12 month study period.</time_frame>
    <description>The development of iris neovascularization and neovascular glaucoma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Exudative Retinal Detachment and Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving dexamethasone implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-treatment group (control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants not receiving dexamethasone implant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravitreal implant</intervention_name>
    <description>Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Ozurdex™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tumor thickness &lt; 9 mm.

          -  Associated serous retinal detachment extending beyond tumor, &gt; one quadrant in extent.

          -  Primary treatment of ocular melanoma with proton irradiation.

        Exclusion Criteria:

          -  Any pre-existing glaucoma.

          -  History of elevated IOP (&gt; 25 mm Hg).

          -  History of steroid response glaucoma.

          -  Active or suspected ocular or periocular infections including most viral diseases of
             the cornea and conjunctiva: active ocular herpes simplex, active epithelial herpes
             simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial
             infections, and fungal diseases.

          -  Any history of ocular herpes simplex.

          -  Torn or ruptured posterior lens capsule.

          -  Known hypersensitivity to any components of the dexamethasone intravitreal implant.

          -  Women of child-bearing potential: pregnant or planning to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana K Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School, Massachusetts Eye and Ear</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary A Lamoureux, BS</last_name>
    <phone>617-573-3067</phone>
    <email>gary_lamoureux@meei.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Marie Lane, MPH</last_name>
    <phone>617-573-3735</phone>
    <email>alane@meei.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>i. Ocular Melanoma Center, Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary A Lamoureux, BS</last_name>
      <phone>617-573-3067</phone>
      <email>gary_lamoureux@meei.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anne Marie Lane, MPH</last_name>
      <phone>617-573-3735</phone>
      <email>alane@meei.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Evangelos S Gragoudas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary E Aronow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Scotto J, Fraumeni JF Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst. 1976 Mar;56(3):489-91.</citation>
    <PMID>1255781</PMID>
  </reference>
  <reference>
    <citation>Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006 Dec;124(12):1684-93.</citation>
    <PMID>17159027</PMID>
  </reference>
  <reference>
    <citation>Gragoudas ES. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4666-73.</citation>
    <PMID>17065472</PMID>
  </reference>
  <reference>
    <citation>Kivelä T, Eskelin S, Mäkitie T, Summanen P. Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2085-93.</citation>
    <PMID>11481276</PMID>
  </reference>
  <reference>
    <citation>Gibran SK, Kapoor KG. Management of exudative retinal detachment in choroidal melanoma. Clin Exp Ophthalmol. 2009 Sep;37(7):654-9. doi: 10.1111/j.1442-9071.2009.02127.x.</citation>
    <PMID>19788660</PMID>
  </reference>
  <reference>
    <citation>Char DH, Bove R, Phillips TL. Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments. Am J Ophthalmol. 2003 Jul;136(1):180-2.</citation>
    <PMID>12834689</PMID>
  </reference>
  <reference>
    <citation>Parrozzani R, Pilotto E, Dario A, Miglionico G, Midena E. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma. Am J Ophthalmol. 2013 Jan;155(1):127-133.e2. doi: 10.1016/j.ajo.2012.06.026. Epub 2012 Sep 18.</citation>
    <PMID>22995029</PMID>
  </reference>
  <reference>
    <citation>Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES. Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma. Trans Am Ophthalmol Soc. 2016 Aug;114:T2.</citation>
    <PMID>27630373</PMID>
  </reference>
  <reference>
    <citation>Malclès A, Nguyen AM, Mathis T, Grange JD, Kodjikian L. Intravitreal dexamethasone implant (Ozurdex®) for exudative retinal detachment after proton beam therapy for choroidal melanoma. Eur J Ophthalmol. 2017 Aug 30;27(5):596-600. doi: 10.5301/ejo.5000940. Epub 2017 Feb 8.</citation>
    <PMID>28218368</PMID>
  </reference>
  <reference>
    <citation>Koehler PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs. 1995 Feb;6(1):19-33. Review.</citation>
    <PMID>7756680</PMID>
  </reference>
  <reference>
    <citation>Sturdza A, Millar BA, Bana N, Laperriere N, Pond G, Wong RK, Bezjak A. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer. 2008 Sep;16(9):1041-8. doi: 10.1007/s00520-007-0395-8. Epub 2008 Feb 7.</citation>
    <PMID>18256860</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Ivana K. Kim</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Uveal Melanoma</keyword>
  <keyword>Steroid-Implant</keyword>
  <keyword>Exudative Retinal Detachment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

